
|Articles|July 1, 2004
Genaera begins more squalamine trials
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
IRIS Registry data mined for understanding of pediatric NK
4
International meta-analysis highlights elevated ocular risk in Clade I Monkeypox
5












































